226 filings
Page 4 of 12
S-8
ir2qye6 nmzker
2 Mar 22
Registration of securities for employees
4:48pm
EFFECT
1qtbpi
2 Mar 22
Notice of effectiveness
12:15am
EFFECT
mmzdwykpp
2 Mar 22
Notice of effectiveness
12:15am
F-3/A
b9fw91r bv096lswpd2
25 Feb 22
Shelf registration (foreign) (amended)
8:52am
CORRESP
ooiuhd
25 Feb 22
Correspondence with SEC
12:00am
UPLOAD
oksfs zxw
23 Feb 22
Letter from SEC
12:00am
F-3
iax0i 52u
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
ngolugzs3 h3
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
z15 zotzmrx8n
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
6-K
0amxmb rf42i
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
6-K
q5y69d fnrh29aat6s
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
6-K
2gxmici 04xtxv
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
2j7ao4giq8a5 pw5blx1
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
qz8ut6vly0
13 Dec 21
ObsEva Appoints Will Brown as Chief Financial Officer
7:00am
6-K
uh46gr
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
424B7
afbzzronlwkl joia
23 Nov 21
Prospectus with selling stockholder info
4:06pm
EFFECT
kukc y0lat959
23 Nov 21
Notice of effectiveness
12:15am
6-K
bmsuxogu
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
CORRESP
sfk2ob
19 Nov 21
Correspondence with SEC
12:00am
UPLOAD
187pg
17 Nov 21
Letter from SEC
12:00am